Have a feature idea you'd love to see implemented?
Let us know!
SLNO Soleno Therapeutics Inc
Price (delayed)
$54.63
Market cap
$2.36B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.7
Enterprise value
$2.31B
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, Diazoxide Choline Controlled-Release (DCCR) tablets, a once-daily oral tablet
Highlights
The EPS has declined by 48% since the previous quarter but it is up by 16% year-on-year
Soleno Therapeutics's net income has plunged by 101% from the previous quarter
Soleno Therapeutics's quick ratio has decreased by 41% QoQ
Key stats
What are the main financial stats of SLNO
Market
Valuations
Earnings
Shares outstanding
43.12M
Market cap
$2.36B
Enterprise value
$2.31B
Price to earnings (P/E)
N/A
Price to book (P/B)
8.02
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$131.16M
EBITDA
-$128.87M
Free cash flow
-$51.63M
Per share
Balance sheet
Liquidity
EPS
-$2.7
Free cash flow per share
-$1.23
Book value per share
$6.81
Revenue per share
$0
TBVPS
$6.91
Total assets
$296.71M
Total liabilities
$32.01M
Debt
$3.03M
Equity
$264.7M
Working capital
$243.24M
Debt to equity
0.01
Current ratio
17.26
Quick ratio
17.16
Net debt/EBITDA
0.35
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-55.2%
Return on equity
-62%
Return on invested capital
-94.5%
Return on capital employed
-46.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SLNO stock price
How has the Soleno Therapeutics stock price performed over time
Intraday
-0.36%
1 week
1.02%
1 month
1.64%
1 year
95.6%
YTD
35.73%
QTD
8.2%
Financial performance
How have Soleno Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$138.47M
Net income
-$131.16M
Gross margin
N/A
Net margin
N/A
The operating income has plunged by 102% from the previous quarter
Soleno Therapeutics's net income has plunged by 101% from the previous quarter
Growth
What is Soleno Therapeutics's growth rate over time
Valuation
What is Soleno Therapeutics stock price valuation
P/E
N/A
P/B
8.02
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 48% since the previous quarter but it is up by 16% year-on-year
The price to book (P/B) is 67% higher than the 5-year quarterly average of 4.8 and 8% higher than the last 4 quarters average of 7.4
SLNO's equity is down by 6% since the previous quarter
Efficiency
How efficient is Soleno Therapeutics business performance
The ROE has soared by 77% YoY but it has contracted by 43% from the previous quarter
The company's return on assets has shrunk by 51% QoQ but it rose by 42% YoY
The return on invested capital has declined by 8% since the previous quarter
Dividends
What is SLNO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SLNO.
Financial health
How did Soleno Therapeutics financials performed over time
SLNO's current ratio is down by 41% QoQ
Soleno Therapeutics's quick ratio has decreased by 41% QoQ
SLNO's debt is 99% smaller than its equity
The company's debt to equity has shrunk by 50% YoY
SLNO's equity is down by 6% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.